Hansa Biopharma Reports First Quarter and Interim January-March 2025 Financial Results ...Middle East

Strong product sales and key progress in pipeline catalysts LUND, Sweden, April 24, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced its interim report for January-March 2025. Peter Nicklin, Chairman of the Board, Hansa Biopharma...

Read More Details
Finally We wish PressBee provided you with enough information of ( Hansa Biopharma Reports First Quarter and Interim January-March 2025 Financial Results )

Also on site :

• Miss Manners: His driving was terrifying. Was I wrong to ask him to slow down?
• The Implications of GLP-1s on Women’s Healthcare
• China, Kenya upgrade ties amid 'turbulent international situation